Updated:
Aptevo Therapeutics
Aptevo Therapeutics was formed in 2016 as a spin-out from Emergent BioSolutions, taking with it bispecific antibody programs in oncology.
Aptevo Therapeutics
Aptevo Therapeutics was formed in 2016 as a spin-out from Emergent BioSolutions, taking with it bispecific antibody programs in oncology. The company is publicly traded on the NASDAQ, not structured as a family office. The firm's drug discovery work centers on the ADAPTIR and ADAPTIR-FLEX platforms, which generate bispecific antibodies designed to co-engage immune cells with tumor targets. Its lead candidate is apotacrit, a bispecific antibody targeting CD3 and the tumor antigen CD37, currently in a Phase 2 trial for relapsed/refractory B-cell non-Hodgkin lymphoma. Another candidate, APVO603, targets 5T4 and is at an earlier preclinical stage. Development has faced challenges: a Phase 2 trial of former candidate ACV-1 (targeting cancer stem cells) was halted in 2021 after interim futility analysis. Total AUM is not applicable — the firm is a public biotech micro-cap, not a capital allocator. The company's annual R&D spend is typically under $20 million (per SEC filings, 2023). It has not disclosed assets under management as it is a drug developer, not an investment vehicle. Aptevo is structurally distinct from family offices in that it is a public company with a market capitalization typically under $50 million, a development-stage biotech. It raises capital through equity offerings and grants rather than managing long-term capital pools. There is no succession or multigenerational governance structure.
General information
Firm type
other
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Seattle
Corporate office
Seattle, WA, United States
Sector focus
Frequently asked questions
Who makes investment decisions at Aptevo Therapeutics?
Aptevo Therapeutics is a publicly traded biotech company, not a family office. Its investment decisions are made by its CEO and board of directors, with strategic input from its scientific advisory board. The company does not have a CIO or deployment team.
What is the primary drug platform of Aptevo?
Aptevo has two proprietary drug platforms: ADAPTIR and ADAPTIR-FLEX. These are bispecific antibody technologies that enable simultaneous targeting of two different antigens, primarily used to activate the immune system against cancer cells.
How is Aptevo structured as a company?
Aptevo is a publicly traded clinical-stage biotech incorporated in Delaware, trading on the NASDAQ. It is not structured as a family office or asset manager. It does not have alternative investment vehicles, co-investment programs, or fund commitments. Its operations are funded through public offerings and licensing.
Where does the underlying capital for Aptevo come from?
Aptevo is a public company listed on the NASDAQ. Its capital comes from public equity markets, including at-the-market offerings and private placements. It is not associated with a family fortune or endowment. The company does not manage outside capital; it operates as a corporate entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: